STOCKS TO BUY: We have identified several stocks that can potentially TRIPLE. Learn more!

Watch Ken As He Describes The Challenges Of Dealing With Hypoparathyroidism In The Workplace And How The Disorder Derailed His Promising Career.

Stock quotes in this article: NPSP 

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, has launched Hypoparathyroidism.com, an educational website for patients and caregivers dealing with this rare and complex disorder. Affecting an estimated 80,000 Americans, hypoparathyroidism is characterized by a number of physical and mental symptoms, including uncontrollable muscle spasms and cramps, tetany, seizures, fatigue, anxiety, and depression.

“The Hypoparathyroidism Association welcomes the launch of Hypoparathyroidism.com and believes it will be an important resource for our community of patients, as well as our caregivers,” said James Sanders, president, Hypoparathyroidism Association, Inc. “As a hypoparathyroidism patient, it is uplifting to see NPS’ recognition of our community needs and its dedication to providing accurate information about this rare disorder that is so often misunderstood.”

The website, Hypoparathyroidism.com, was developed in conjunction with experts in the field as a resource to connect patients with hypoparathyroidism, their families, and the healthcare professionals who treat them and provide information for those seeking knowledge about the endocrine condition. It offers first-hand patient experiences and numerous downloadable resources including guidance on how to talk to your doctor about the disorder and how to track calcium, vitamin D and phosphorus levels in foods. Using video and easy-to-understand text, the website provides an in-depth look at the causes and symptoms of the disorder. Hypoparathyroidism.com is also designed to meet the needs of healthcare professionals interested in knowing more about this rare disorder. It provides them with an overview of diagnosis and management, an animation explaining the mechanism of the disorder and links to peer-reviewed journal articles for in-depth exploration.

“Diagnosing the condition that they suffer from is often a critical component for those living with a rare disorder, especially for patients coping with symptoms that are uncommon and imply multiple organ systems,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “As such, we are proud to launch Hypoparathyroidism.com, as our contribution to offering patients and healthcare providers a dedicated educational resource that focuses on the unique needs of the hypoparathyroidism community.”

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
TRY IT FREE
New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,179.85 109.67 0.73%
NASDAQ 3,452.13 28.57 0.83%
S&P 500 1,639.04 12.31 0.76%
US 10 Yr 2.171% +0.045

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs